ASPG and COVID-19: Therapy for ALL/LLy is unique; it lasts approximately 2.5 years and can exacerbate COVID-19–related complications (eg, pancreatitis and thrombosis caused by asparaginase and obesity, diabetes, and lymphopenia-related severe viral infection associated with glucocorticoids).